摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,2,4,4-Tetrachloro-7-oxa-1,3,5,11-tetraaza-2I>>5,4I>>5,6I>>5-triphospha-spiro[5.5]undeca-1(6),2,4-triene | 93554-77-9

中文名称
——
中文别名
——
英文名称
2,2,4,4-Tetrachloro-7-oxa-1,3,5,11-tetraaza-2I>>5,4I>>5,6I>>5-triphospha-spiro[5.5]undeca-1(6),2,4-triene
英文别名
2,2,4,4-tetrachloro-7-oxa-1,3,5,11-tetraza-2λ5,4λ5,6λ5-triphosphaspiro[5.5]undeca-1(6),2,4-triene
2,2,4,4-Tetrachloro-7-oxa-1,3,5,11-tetraaza-2I>>5,4I>>5,6I>>5-triphospha-spiro[5.5]undeca-1(6),2,4-triene化学式
CAS
93554-77-9
化学式
C3H7Cl4N4OP3
mdl
——
分子量
349.848
InChiKey
WRBOBQGQBHGHQP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    15
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    58.3
  • 氢给体数:
    1
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    带有P–NH基团的环三磷苯环的去质子反应产生的桥连环磷腈†
    摘要:
    环三磷腈侧链中含有P–NHR基团的衍生物在强碱的存在下反应,形成稳定的分子间桥连产物。的反应氢化钠带有P-NH基,N 3 P 3 Cl 4 [O(CH 2)3 NH],(1a)或N 3 P 3 Cl 4 [CH 3 N(CH 2)3 NH]的单螺环磷腈衍生物,(1b)导致形成与八元环磷腈环桥联的双环磷腈(ansa)(2a,2b),而氢化钠具有单氨基环磷腈衍生物[N 3 P 3 Cl 5(NHR),R =正己基,3a;i -Pr,3b ; Ph,3c ]给出双螺旋环与四元环磷腈环以螺环排列方式桥接(4a–c)。在后面的反应中,由于水解反应与溶剂四氢呋喃中的水分有关,还获得了P-O-P桥接化合物(5a-c)。另外,发现环三磷腈与单螺化合物(1a)或(1b)在存在下氢化钠导致形成不对称桥联环磷腈(6a–b)的第一个实例。
    DOI:
    10.1039/c1dt10073d
  • 作为产物:
    描述:
    3-氨基-1-丙醇六氯环三磷腈三乙胺 作用下, 以 四氢呋喃 为溶剂, 反应 6.0h, 以80%的产率得到2,2,4,4-Tetrachloro-7-oxa-1,3,5,11-tetraaza-2I>>5,4I>>5,6I>>5-triphospha-spiro[5.5]undeca-1(6),2,4-triene
    参考文献:
    名称:
    On the scent of asymmetrical dandelion dendrimers
    摘要:
    Starting materials for the design of asymmetrical dandelion dendrimers were synthesized upon the preliminary fixation of suitable amino-alcohols on hexachlorocyclotriphosphazene, N3P3Cl6, as ''blockers''. Further linkage of diamines on solid supports leads to the expected asymmetrical moieties. (C) 1997 Elsevier Science B.V.
    DOI:
    10.1016/s0022-2860(97)00007-0
点击查看最新优质反应信息

文献信息

  • Cyclotriphosphazene derivatives with three different chiral centres: Synthesis, characterization and investigation of their stereogenic properties
    作者:Şule Şahin Ün、Elif Özcan、Aylin Uslu、Fatma Yuksel、Adem Kılıç
    DOI:10.1016/j.poly.2013.06.050
    日期:2013.10
    to give diastereoisomers containing two different chiral centres, N3P3Cl2[O(CH2)3NH][O(CH2)2NMe] (2–3), which are also trans (2) and cis (3) geometric isomers. Compounds 2 and 3 were reacted separately with another unsymmetrical reagent, N-methyl-1,3-propanediamine, to describe the stereogenic properties of cyclotriphosphazenes combined with three different centres of chirality. The compounds N3P3
    摘要使单螺环磷腈衍生物N3P3Cl4 [O(CH2)3NH](1)与不对称试剂2-甲基氨基乙醇反应,制得含有两个不同手性中心N3P3Cl2 [O(CH2)3NH] [O(CH2)2NMe的非对映异构体](2-3),它​​们也是反式(2)和顺式(3)几何异构体。化合物2和3分别与另一种不对称试剂N-甲基-1,3-丙二胺反应,以描述结合三个不同手性中心的环三磷腈的立体异构性质。化合物N3P3 [O(CH2)3NH] [O(CH2)2NMe] [HN(CH2)3NMe](4-7),命名为反式-反式,反式-顺式,顺式-顺式,顺式-反式异构体分别从这些反应中获得。分离所有化合物,使用硅胶柱色谱分离非对映异构体,并通过元素分析,质谱和31P和1H NMR光谱对这些新型化合物进行了分析。另外,化合物2、3、4和6的结构通过X射线晶体学确定。通过添加手性溶剂(CSA),(R)-(+)-2,2,2-三氟-1的31P
  • Regiochemical Control in the Substitution Reactions of Cyclotriphosphazene Derivatives with Secondary Amines
    作者:Serap Beşli、Ceylan Mutlu Balcı、Semih Doğan、Christopher W. Allen
    DOI:10.1021/acs.inorgchem.8b01620
    日期:2018.10.1
    of two different secondary amines with some N3P3Cl4R2 (R2 = OCH2CH2CH2NH, NHPh, NHBut) derivatives lead to the formation of geminal products. We have shown that this observation depends on the electron-donating properties of the PR2 groups. Isolated compounds were analyzed by standard techniques such as elemental analysis, mass spectrometry, and 1H and 31P NMR spectroscopy. The structures of compounds
    单螺和双取代环三磷腈衍生物N 3 P 3 Cl 4 R 2(R 2 = OCH 2(CF 2)2 CH 2 O(1a),SPh(1b),OCH 2 CH 2 CH 2 O(1c),NHPh(1d),OCH 2 CH 2 CH 2 NH(1e),NHBu t(1f)))用两种仲胺(吡咯烷和二甲胺)进行了研究,研究了混合取代基环磷腈中的双键或非双键定向作用。从反应混合物的31 P NMR光谱定量确定了同构产物的相对量,即双子叶和非双子叶的顺式或反式。尽管仲胺在与六氯环三磷腈的反应中通常遵循非结构途径,但在这项工作中,两种不同的仲胺与一些N 3 P 3 Cl 4 R 2(R 2 = OCH 2 CH 2 CH 2 NH,NHPh ,NHBu Ť)衍生物会导致双子星产品的形成。我们已经表明,这一观察结果取决于PR 2基团的供电子特性。分离的化合物通过标准技术进行分析,例如元素分析,质谱以及1 H和31
  • Synthesis and characterization of the first geminal dibenzylaminocyclotriphosphazene derivatives
    作者:Serap Beşli、Ceylan Mutlu Balcı、Ceren Köseoğlu、Duygu Palabıyık、Christopher W. Allen
    DOI:10.1016/j.ica.2019.04.022
    日期:2019.6
    N3P3Cl4[NHBut]2 with dibenzlyamine led to formation of bis geminal dibenzylamino derivatives (4d and 4e). The reaction of N3P3Cl4[NHPh]2 was carried out with dibenzylamine at the same mole ratio, leading to the fully substituted product (5c) where four chloride atoms replaced with dibenzylamino groups. The first examples of geminal dibenzylamino cyclotriphosphazene compounds (4d, 4e and 5c) were obtained.
    摘要本文研究了二苄胺与选定的单螺和双取代的双取代的环三磷腈衍生物N3P3Cl4R2 [R2 =(OCH2(CF2)2CH2O)(1a); SPh(1b);NHPh(1c);系统地研究了(OCH2CH2CH2NH)(1d)和NHBut(1e)]。研究了PR2基团的电子供应特性对反应途径和产物取代度的影响。N3P3Cl4 [NH(CH2)3O]和N3P3Cl4 [NHBut] 2与二苯甲胺的氨解反应导致形成双双双二苄基氨基衍生物(4d和4e)。N3P3Cl4 [NHPh] 2与二苄基胺以相同的摩尔比进行反应,得到完全取代的产物(5c),其中四个氯原子被二苄基氨基取代。双苄基二苄氨基环三磷腈化合物的第一个例子(4d,
  • The role of the substituted group on competitive formation of ansa and spiro isomers
    作者:Duygu Palabıyık、Ceylan Mutlu Balcı、Serap Beşli
    DOI:10.1016/j.ica.2018.11.047
    日期:2019.3
    the presence of two different bases, NaH and Et3N. The relative amounts of isomeric products, spiro and ansa were established quantitatively from the 31P NMR spectra of the reaction mixtures. The products were separated and characterized by elemental analysis, mass spectrometry, 1H and 31P NMR spectroscopy. Crystal structures of 2b, 3b, 2e and 2f have been characterized by X-ray crystallography. Although
    摘要本文对环三磷腈及其衍生物N3P3Cl4R2 [R2 = Cl(1a); (OCH 2(CF 2)2 CH 2 O)(1b);(OCH2CH2CH2O)(1c);NHPh(1天);(OCH 2 CH 2 CH 2 NH)(1e)和NHBut(1f)]已经用1,3-丙二醇进行了。在两种不同的碱(NaH和Et3N)存在下,化合物1a-f与THF溶液中的1,3-丙二醇以1:1的摩尔比反应。根据反应混合物的31 P NMR光谱定量确定异构体产物螺和ansa的相对量。分离产物,并通过元素分析,质谱,1H和31P NMR光谱表征。2b,3b,2e和2f的晶体结构已通过X射线晶体学表征。
  • Competitive formation of cis and trans derivatives in the nucleophilic substitution reactions of cyclophosphazenes having a mono-spiro P–NHR group
    作者:Serap Beşli、Simon J. Coles、David B. Davies、Adem Kılıç、Elif Okutan、Robert A. Shaw、Esra Tanrıverdi Eçik、Gönül Yenilmez Çiftçi
    DOI:10.1039/c1dt10176e
    日期:——
    derivative of compound 2. For each reaction the relative proportions of cis and trans isomers were determined by 31P NMR measurements of the reaction mixtures. It was found that the reactions of compound 1 with all three alcohols and of compound 2 with methanol lead to exclusive formation of isomers with the substituent cis to the NH moiety, whereas all other reactions lead to mixtures of cis and trans
    N 3 P 3 Cl 4 [NH(CH 2)3 NMe](1)和N 3 P 3 Cl 4 [NH(CH 2)3 O](2)与单官能醇的亲核取代反应(甲醇, 2,2,2-三氟乙醇, 苯酚)和仲胺(吡咯烷)被用于研究进入的亲核试剂与具有取代基的产品的比例之间的关系,所述取代基是顺式或反式的螺环NH部分。通过元素分析,质谱,1 H和31 P NMR光谱对反应产物进行表征,并通过X射线晶体学对其进行构型异构体的表征。六种产品的特征是该醇的螺NH基团具有顺式取代基(甲醇, 苯酚)和化合物1和2的吡咯烷衍生物,与仅一个具有取代基的反式为螺环NH基团的衍生物相比,则为化合物2的吡咯烷衍生物。对于每个反应,通过反应混合物的31 P NMR测量确定顺式和反式异构体的相对比例。结果发现,化合物的反应中1与所有三个醇和化合物2与甲醇导致在NH部分带有顺式取代基的异构体排他性形成,而所有其他反应在标准反应条件下导
查看更多

同类化合物

曲磷胺 曲磷胺 异环磷酰胺杂质F 异环磷酰胺 [(2-羟基-2-氧代-1,4,2-氧氮杂磷杂环己烷-4-基)甲基]膦酸 4-过氧化氢异环磷酰胺 4-氧代异环磷酰胺 4-乙基-7-甲基-7-氮杂-2,6-二氧杂-1-磷杂双环[2.2.2]辛烷1-硫化物 2’-氧代异环磷酰胺 2-[2-氯乙基-[3-(2-氯乙基)-2-氧代-1-氧杂-3-氮杂-2-磷杂环己-2-基]氨基]乙基甲烷磺酸酯 2,3,4,6,7,8-六氢-[1,3,2]氧氮杂膦咛并[2,3-b][1,3,2]氧氮杂膦咛 (2-氯-乙基)-[(R)-3-(2-氯-乙基)-2-氧代-2lambda5-[1,3,2]氧氮杂磷杂环己烷-2-基]-胺 (2R*,4aS*,8aR*)-1-methyl-2-phenyl-1,4,4a,5,6,7,8,8a-octahydro-2H-3,1,2-benzoxazaphosphinine 2-oxide (2S*,4aS*,8aR*)-2-phenyl-1,4,4a,5,6,7,8,8a-octahydro-2H-3,1,2-benzoxazaphosphinine 2-oxide (2R*,4aS*,8aS*)-1-methyl-2-phenyl-1,4,4a,5,6,7,8,8a-octahydro-2H-3,1,2-benzoxazaphosphinine 2-oxide (2S*,4aS*,8aS*)-2-phenyl-1,4,4a,5,6,7,8,8a-octahydro-2H-3,1,2-benzoxazaphosphinine 2-oxide (S,S)-2-oxo-2-propionyl-1,3,2-oxaphosphorinane 2-(Dimethylamino)-3-phenyl-1,3,2-oxazaphosphorinane 2-(1,1,1,3,3,3-Hexafluoroisopropoxy)-3,5,5-trimethyl-1,3,2-oxazaphosphorinane cis-2-(1,1,1,3,3,3-Hexafluoroisopropoxy)-3-methyl-5-tert-butyl-1,3,2-oxazaphosphorinane 2-(1,1,1,3,3,3-Hexafluoroisopropoxy)-3-methyl-1,3,2-oxazaphosphorinane 2-(1,1,1,3,3,3-Hexafluoroisopropoxy)-3-phenyl-1,3,2-oxazaphosphorinane 3,3,5,5-tetramethyl-2-oxido-2-oxo-1,4,2-oxaazaphosphorinane 2-(2-chloroethylamino)-3-(1-methyl-2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide 4-ethyl-2-hydroxy-2-oxo-tetrahydro-4H-1,4,2-oxazaphosphorine geranyloxyifosfamide 4-methoxy-ifosfamide (2-chloroethyl)-[3-(2-chloroethyl)-2-oxo-4-pentyloxy-2λ5-[1,3,2]oxazaphosphinan-2-yl]amine 3-ethyl-2-hydroxy-2-oxo-1,4,2-oxazaphosphorinane Methyl-[3-(3-methyl-[1,3,2]oxazaphosphinan-2-yloxy)-propyl]-amine 2-Oxo-3-(propan-2-yl)-1,3,2-oxazaphosphinan-2-ium 3-(2-Chloroethyl)-2-(2-chloroethyl)amino-4-hydroxytetrahydro-2H-1,3,2-oxazaphosphorine 3-(2-Chloroethyl)-2-(1-ethyl-2-mesyloxyethylamino)-tetrahydro-2H-1,3,2-oxazaphosphorin-2-oxide 2H-1,3,2-Oxazaphosphorine, 2-fluorotetrahydro-3,5-dimethyl-, 2-oxide 2H-1,3,2-Oxazaphosphorine, 2-fluorotetrahydro-3,4-dimethyl-, 2-oxide (3-Isopropyl-2-oxo-2λ5-[1,3,2]oxazaphosphinan-2-yl)-acetic acid methyl ester cis-2-mesityl-2-oxo-3-phenyl-5-tert-butyl-1,3,2λ5-oxazaphosphorinane trans-2-mesityl-2-oxo-3-phenyl-5-tert-butyl-1,3,2λ5-oxazaphosphorinane (2S,6S)-2-Benzyl-3-(1,1-diethyl-propyl)-6-methyl-[1,3,2]oxazaphosphinane 2-oxide (2R,6S)-2-Benzyl-3-(1,1-diethyl-propyl)-6-methyl-[1,3,2]oxazaphosphinane 2-oxide (2S,6S)-2-((E)-2-Allyloxy-but-2-enyl)-3-tert-butyl-6-methyl-[1,3,2]oxazaphosphinane 2-oxide (2R,6S)-2-((E)-2-Allyloxy-but-2-enyl)-3-tert-butyl-6-methyl-[1,3,2]oxazaphosphinane 2-oxide (S)-(2l,6l)-2-(methoxymethyl)-6-methyl-3-(1-methylethyl)-1,3,2-oxazaphosphorinane 2-sulfide (S)-1-((2S,6S)-3-tert-Butyl-6-methyl-2-oxo-2λ5-[1,3,2]oxazaphosphinan-2-yl)-3-methyl-hex-5-en-2-one 2-methoxy-1,3,2-oxazaphosphinane 3-(2-Chloroethyl-2-<(2-chloroethyl)-(3-mesyloxytrimethylen)-amino>-tetrahydro-2H-1,3,2-oxazaphosphorin-2-oxide 2-chloro-3-[(S)-α-methylbenzyl]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide (S)-(2u,6l)-3-(1,1-Diethylpropyl)-6-methyl-2-(2-propenyl)-1,3,2-oxazaphosphorinane 2-oxide 3-(2-chloro-ethyl)-2-(2-hydroxy-ethylamino)-2-oxo-2λ5-[1,3,2]oxazaphosphinan-4-one isopropyl-[3-(3-isopropyl-[1,3,2]oxazaphosphinan-2-yloxy)-propyl]-amine